● Recruiting

The Efficacy of Neoadjuvant Chemoradiotherapy in Comparison With Neoadjuvant Chemotherapy in Patients With Resectable Squamous Cell Esophageal Cancer

Condition: Esophageal Cancer · Sponsor: Blokhin's Russian Cancer Research Center

PhasePhase 3

Planned participants156

Who can joinAll sexes, 18 Years to 70 Years

Healthy volunteersYes

About this study

The purpose of this study is to evaluate the safety, feasibility and outcomes of neoadjuvant chemotherapy followed by esophagectomy versus neoadjuvant chemoradiotherapy followed by esophagectomy for locally advanced resectable esophageal squamous cell carcinoma cT3-4aN0M0, cT1-4aN1-3M0. This is non-inferiority study (neoadjuvant chemoradiotherapy has no advantage over neoadjuvant chemotherapy).

This description comes directly from the study's public registry record.

Talk to the study team

Omar Abouhaidar, MD, PhD · +79269125902 · abouhaidar@yandex.ru

Parvin Akhmedov · +79267333323 · Akhmedovparvin@gmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

N.N. Blokhin National Medical Research Center of Oncology

Moscow, Russia

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05547529